Citizens expect science to be a driving force that will support the transition towards a greener and fairer society. Translational research can play a crucial role in this transition if excellent research results and data are quickly made available and translated into practical use across Europe. Through its core mission, EATRIS strives to support the exploitation and uptake of research and innovation results beyond the “valley of death” and their transformation into sustainable solutions for patients and a healthier society, thereby increasing the impact of research and innovation investment.
To evidence EATRIS’ contribution to enabling the uptake of research and innovation results, we track key performance indicators that reflect how EATRIS facilitates access to high-quality translational research outputs. In 2025, EATRIS open access resources* were accessed by nearly 7000 users across its toolboxes and digital platforms, and EATRIS contributed to or was acknowledged in 148 scientific publications, demonstrating active use and dissemination. Since 2020, this has amounted to nearly 20k users engaging with EATRIS open access resources and 602 publications involving or citing EATRIS, illustrating sustained support for the uptake and reuse of research and innovation results to maximise the impact of public investment in health research.
*EATRIS open access resources are: ODDG, MOTBX, IMT, PERC, RIS (under reconstruction), Innovation Helpdesk.
Examples of our work in this area:
Successful Partnerships in the Health Innovations
EATRIS is a partner in the RECOGNISED project that investigates the link between retina changes and cognitive disorder in type 2 diabetes.
EU-PEARL (project) Platform Trial Master Protocol Paves Way in Rare Genetic Disease Research
EATRIS was a partner in the EU-PEARL project that established a “plug and play” system for drug development, offering cost-effectiveness and the ability to assess a drug’s viability within approximately 36 months. The Children’s Tumor Foundation and the Global Coalition for Adaptive Research are have now joined forces to use this framework for trials in rare genetic conditions.
